Gain Therapeutics grants CEO 200,000 stock options

Gain Therapeutics, Inc. reported that CEO and President Gene Mack received a grant of 200,000 employee stock options to buy common stock at an exercise price of $1.86 per share.

Rhea-AI Filing Summary

Gain Therapeutics, Inc. reported that CEO and President Gene Mack received a grant of 200,000 employee stock options to buy common stock at an exercise price of $1.86 per share. All 200,000 options were newly awarded and represent his total option holdings reported after this grant.

The options expire on March 24, 2036. According to the vesting terms, 25% of the underlying shares vest on March 24, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, as long as he continues in service through each vesting date.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 1 txn

Insider Mack Gene

Role CEO, President

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	200,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 200,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the option shall vest as to 25% on March 24, 2027, and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Gain Therapeutics (GANX) Form 4 report for CEO Gene Mack?

The Form 4 reports that CEO and President Gene Mack received a grant of 200,000 employee stock options. These options give him the right to buy Gain Therapeutics common stock at a fixed exercise price, subject to long-term vesting conditions and an expiration date in 2036.

How many Gain Therapeutics (GANX) stock options were granted to the CEO and at what price?

Gene Mack was granted 200,000 employee stock options, each with an exercise price of $1.86 per share. This means he can purchase Gain Therapeutics common stock at that price once the options vest, subject to the stated vesting schedule and expiry date.

What is the vesting schedule for Gene Mack’s Gain Therapeutics (GANX) stock options?

The options vest 25% on March 24, 2027, with the remaining 75% vesting in 36 equal monthly installments afterward. Vesting is contingent on his continuous service with Gain Therapeutics through each vesting date, linking the award to long-term employment.

When do Gene Mack’s Gain Therapeutics (GANX) stock options expire?

The 200,000 stock options granted to Gene Mack expire on March 24, 2036. After that date, any unexercised options become worthless, so exercise must occur after vesting but before expiration, in accordance with the award’s specific terms.

How many Gain Therapeutics (GANX) stock options does Gene Mack hold after this grant?

After this grant, Gene Mack is reported as holding 200,000 employee stock options. This figure reflects the total number of derivative securities reported in this filing, all associated with the new award of options to purchase Gain Therapeutics common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/26/2026 - 08:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mack Gene

(Last) (First) (Middle)

C/O GAIN THERAPEUTICS, INC.

4800 MONTGOMERY LANE, SUITE 220

(Street)

BETHESDA MARYLAND 20814

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Gain Therapeutics, Inc. [ GANX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.86	03/24/2026		A		200,000		(1)	03/24/2036	Common Stock	200,000	$0	200,000	D

Explanation of Responses:

1. The shares underlying the option shall vest as to 25% on March 24, 2027, and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.

	/s/ Gene Mack	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)